Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

IO Biotech (IOBT) announced data from the NSCLC cohort in the company’s Phase 2 basket trial of IO102-IO103, the company’s lead investigational candidate, given in combination with Merck’s anti-PD-1 ...

The Official Film Chart is a rundown of the UK’s favourite films of the week, as bought on DVD, Blu-Ray and download and is compiled by the Official Charts Company, based on sales across a seven ...

Brooks will officially take over the role of CEO on Jan. 4, after current CEO Sean Wells steps down on Jan. 3. Brooks received his bachelor's and master's degrees from Southeast Missouri State ...

Merck (NYSE: MRK) and Moderna , Inc. (Nasdaq: NASDAQ:MRNA) have announced the commencement of a Phase 3 clinical trial, INTerpath-009, to evaluate the efficacy of V940 (mRNA-4157) in conjunction with ...

in combination with Keytruda, Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with resectable Stage II, IIIA or IIIB non-small cell lung cancer who did not achieve a pathological ...

The INTerpath-009 trial will investigate an individualized neoantigen therapy plus Keytruda in patients with non-small cell lung cancer post-surgery whose disease didn't fully respond to prior ...

NEW YORK – Moderna and Merck will test their personalized neoantigen cancer vaccine V940 with Merck's checkpoint inhibitor Keytruda (pembrolizumab) in certain non-small cell lung cancer patients in a ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless ...